Clinical trial
A Phase 1 Dose-Escalation Study To Assess the Safety and Tolerability of LX214 Ophthalmic Solution in Healthy Volunteers, Followed By an Open-Label Evaluation of LX214 Ophthalmic Solution in Patients With Keratoconjunctivitis Sicca
NCT00851734 is registered in ClinicalTrials.gov with Lux Biosciences, Inc. as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- A Phase 1 Dose-Escalation Study To Assess the Safety and Tolerability of LX214 Ophthalmic Solution in Healthy Volunteers, Followed By an Open-Label Evaluation of LX214 Ophthalmic Solution in Patients With Keratoconjunctivitis Sicca
- Lead sponsor
- Lux Biosciences, Inc.
- Phase
- Phase 1
- Overall status
- Completed
- Start date
- February 28, 2009
- Completion date
- April 30, 2009
- Enrollment
- 35 (actual)
- Sites
- 1
Conditions
As the registry lists them; a condition with its own page is linked.